Objective:

To evaluate the long-term efficacy and safety of bimekizumab in patients with moderate to severe plaque psoriasis over a 3-year period.

Approach:

Key Findings:

• At week 4, bimekizumab showed higher rates of symptom resolution compared to secukinumab: no itching (34% vs 25.1%), no skin pain (74.5% vs 60%), no scaling (46.1% vs 21.6%).
• At year 1, the rates improved for bimekizumab: no itching (60.9% vs 48.1%), no skin pain (78.6% vs 70.8%), no scaling (70.5% vs 49.7%).
• At year 3, concurrent achievement of PASI score of 0 and DLQI score of 0 or 1 was reported in 62.2% of continuous bimekizumab patients and 63.8% of those who switched from secukinumab.

Interpretation:

Bimekizumab demonstrated rapid and sustained improvements in psoriasis symptoms and health-related quality of life over 3 years.

Limitations:

• Eligibility criteria may limit generalizability to broader patient populations.
• Open-label extension phase lacked treatment blinding, potentially introducing bias in patient-reported outcomes.

Conclusion:

Bimekizumab effectively improved symptoms and quality of life in patients with moderate to severe plaque psoriasis over a 3-year period.

Sources:

• JAMA Dermatology
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.